A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

Inclusion Criteria:

1. Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification

2. Participants must be on lipid-lowering therapy that should adhere to standard ofcare (SOC) per local guidelines. Lipid-lowering medications should be optimized andstabilized for at least 4 weeks prior to screening to minimize changes in thesemedications during the study.

3. Participants must be willing to comply with diet and lifestyle recommendations asable.

Exclusion Criteria:

1. Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening

2. Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal

3. Total bilirubin > 1.5 ULN unless due to Gilbert's syndrome

4. Estimated GFR < 30 mL/min/1.73 m^2